Preventive pipac after surgery for high-risk colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment called PIPAC (a way to deliver chemotherapy directly into the abdomen) given after surgery for high-risk colorectal cancer. It aims to reduce the chance of cancer coming back in the abdominal area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery for colorectal cancer that started in the colon or upper rectum, either as an emergency or planned procedure.
- Your cancer is considered high risk (stage pT4) or has cancer cells in the abdominal fluid or limited spread to one area of the abdomen that was removed during surgery. It must not have spread to other organs.
- You are between 18 and 80 years old.
- You are generally active and able to care for yourself (performance status 0-1).
- You have not had chemotherapy or radiation before the surgery, and you do not have a hereditary form of colorectal cancer or MSI-high cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a treatment given directly into the liver after surgery to remove colorectal cancer that has spread to the liver. The goal is to see if this treatment lowers the chance of the cancer coming back.
This Phase 2 study tests whether spraying chemotherapy into the abdomen (through a small procedure) after colon cancer surgery can lower the chance the cancer comes back. It is meant for people with high-risk tumor features but who have had surgery and have no proven relapse yet.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
This study tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for women with advanced ovarian cancer who cannot have surgery to remove all tumors. The goal is to see if this approach is safe and helps slow cancer growth.
This trial tests if a special type of chemotherapy delivered as a mist during surgery (PIPAC) can help prevent the spread of stomach cancer. It is for people with advanced but not yet metastatic stomach cancer who have not had prior treatment.
Hear when a new Colorectal Cancer Control and Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.